{"classes":[{"categories":[{"measurements":[{"comment":"Could not be calculated due to the low number of events","groupId":"OG000","lowerLimit":"2.2","upperLimit":"NA","value":"9.0"},{"comment":"Could not be calculated due to the low number of events","groupId":"OG001","lowerLimit":"4.2","upperLimit":"NA","value":"10.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"IDH1/2 mutation"},{"categories":[{"measurements":[{"comment":"Could not be calculated due to the low number of events","groupId":"OG000","lowerLimit":"0.9","upperLimit":"NA","value":"9.8"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"10.9","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"FLT3 mutation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.\n\nOverall survival was analyzed in participants with the following molecular markers:\n\n* Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutation\n* FMS (Feline McDonough Sarcoma)-like tyrosine kinase 3 (FLT3) mutation","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received matching placebo to venetoclax orally once a day (QD) plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG000","title":"Placebo + Low Dose Cytarabine (LDAC)"},{"description":"Participants received venetoclax 600 mg orally once a day plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG001","title":"Venetoclax + Low Dose Cytarabine (LDAC)"}],"paramType":"MEDIAN","populationDescription":"The full analysis set; participants in each mutation subgroup","reportingStatus":"POSTED","timeFrame":"From randomization until the primary analysis cut-off date of February 15, 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.","title":"Overall Survival (OS) by Mutation Subgroups","type":"SECONDARY","unitOfMeasure":"months"}